We are live on ! Find out more
ARDS

Aridis Pharmaceuticals Inc. Common Stock
ARDS

Delisted

ARDS was delisted on the 18th of July, 2023.

Back to rankings

5 hedge funds and large institutions have $642K invested in Aridis Pharmaceuticals Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

299% more capital invested

Capital invested by funds: $161K → $642K (+$481K)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

25% more funds holding

Funds holding: 4 → 5 (+1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$422K
2
MWNA
Marshall Wace North America
New York
+$176

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$12.5K
2
UBS Group
UBS Group
Switzerland
-$3.46K
3
TRCT
Tower Research Capital (TRC)
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$502K +$422K +45,665 New
Millennium Management
2
Millennium Management
New York
$118K -$12.5K -1,349 -11%
UBS Group
3
UBS Group
Switzerland
$19K -$3.46K -375 -19%
Wells Fargo
4
Wells Fargo
California
$3K – – –
TRCT
5
Tower Research Capital (TRC)
New York
– -$2K -158 Closed
MWNA
6
Marshall Wace North America
New York
– +$176 +19 New

ARDS Hedge Fund Activity: Q1 2019 in Review

5 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q1 2019, worth a combined $642K — up 299% from $161K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ARDS positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $422K. The largest seller was Millennium Management, cutting an estimated $12.5K.

  • 5 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q1 2019, up from 4 in Q4 2018.
  • Funds reported $642K of Aridis Pharmaceuticals Inc. Common Stock stock for Q1 2019, up 299% quarter-over-quarter.
  • 2 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q1 2019 and 1 closed out, a net change of +1 holder.
  • The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q1 2019 was Vanguard Group, an estimated $422K added.
  • The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q1 2019 was Millennium Management, an estimated $12.5K sold.

Based on aggregated 13F filings for Q1 2019.